These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38300959)

  • 1. Survival according to the site of metastasis in triple-negative breast cancer patients: The Peruvian experience.
    Piedra-Delgado L; Chambergo-Michilot D; Morante Z; Fairen C; Jerves-Coello F; Luque-Benavides R; Casas F; Bustamante E; Razuri-Bustamante C; Torres-Roman JS; Fuentes H; Gomez H; Narvaez-Rojas A; De la Cruz-Ku G; Araujo J
    PLoS One; 2024; 19(2):e0293833. PubMed ID: 38300959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the Delayed Initiation of Adjuvant Chemotherapy in the Outcome of Triple Negative Breast Cancer.
    Morante Z; Ruiz R; Araujo JM; Pinto JA; Cruz-Ku G; Urrunaga-Pastor D; Namuche F; Flores C; Mantilla R; Luján MG; Fuentes H; Schwarz L; Aguilar A; Neciosup S; Gómez HL
    Clin Breast Cancer; 2021 Jun; 21(3):239-246.e4. PubMed ID: 33221201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subpopulation treatment effect pattern plot analysis: a prognostic model for distant recurrence-free survival to estimate delayed adjuvant chemotherapy initiation effect in triple-negative breast cancer.
    Morante Z; Ferreyra Y; Pinto JA; Valdivieso N; Castañeda C; Vidaurre T; Valencia G; Rioja P; Fuentes H; Cotrina JM; Neciosup S; Gomez HL
    Front Oncol; 2023; 13():1193927. PubMed ID: 38023174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple-negative breast cancer in Peru: 2000 patients and 15 years of experience.
    De-la-Cruz-Ku G; Luyo M; Morante Z; Enriquez D; Möller MG; Chambergo-Michilot D; Flores L; Luque R; Saavedra A; Eyzaguirre-Sandoval ME; Luján-Peche MG; Noel N; Calderon H; Razuri C; Fuentes HA; Cotrina JM; Neciosup SP; Araujo J; Lema A; Pinto J; Gomez HL; Valcarcel B
    PLoS One; 2020; 15(8):e0237811. PubMed ID: 32833983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
    Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological features and prognostic evaluation of bone metastasis in triple-negative breast cancer.
    Luo A; Wu F; Han R; Huang S; Zhang Y; Jing X; Zhao X
    J Cancer Res Ther; 2017; 13(5):778-784. PubMed ID: 29237903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of Site-Specific Metastases and Surgery in De Novo Stage IV Triple-Negative Breast Cancer: A Population-Based Analysis.
    Gu Y; Wu G; Zou X; Huang P; Yi L
    Med Sci Monit; 2020 Feb; 26():e920432. PubMed ID: 32043484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
    Wu SY; Tan Y; Guan YS
    Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk and prognostic factors of breast cancer with liver metastases.
    Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
    BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymph node ratio as best prognostic factor in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy.
    De la Cruz-Ku GA; Chambergo-Michilot D; Valcarcel B; Rebaza P; Möller M; Araujo JM; Enriquez D; Morante Z; Razuri C; Luque R; Saavedra A; Eyzaguirre E; Lujan M; Noel N; Pinto J; Cotrina J; Gomez H
    Breast J; 2020 Sep; 26(9):1659-1666. PubMed ID: 32713113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for distant metastasis of patients with primary triple-negative breast cancer.
    Yao Y; Chu Y; Xu B; Hu Q; Song Q
    Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31113872
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer.
    Diessner J; Wischnewsky M; Stüber T; Stein R; Krockenberger M; Häusler S; Janni W; Kreienberg R; Blettner M; Schwentner L; Wöckel A; Bartmann C
    BMC Cancer; 2016 May; 16():307. PubMed ID: 27175930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does addition of postmastectomy radiotherapy improve outcome of patients with pT1-2, N0 triple negative breast cancer as compared to breast conservation therapy?
    Raghavan RK; Ibrahim S; Jagathnath Krishna KM; Mathew BS
    J Cancer Res Ther; 2019; 15(5):1031-1034. PubMed ID: 31603106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients.
    Urru SAM; Gallus S; Bosetti C; Moi T; Medda R; Sollai E; Murgia A; Sanges F; Pira G; Manca A; Palmas D; Floris M; Asunis AM; Atzori F; Carru C; D'Incalci M; Ghiani M; Marras V; Onnis D; Santona MC; Sarobba G; Valle E; Canu L; Cossu S; Bulfone A; Rocca PC; De Miglio MR; Orrù S
    BMC Cancer; 2018 Jan; 18(1):56. PubMed ID: 29310602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparisons of Oncologic Outcomes between Triple-Negative Breast Cancer (TNBC) and Non-TNBC among Patients Treated with Breast-Conserving Therapy.
    Kim S; Park HS; Kim JY; Ryu J; Park S; Kim SI
    Yonsei Med J; 2016 Sep; 57(5):1192-8. PubMed ID: 27401651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
    Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
    Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of Modified Ruji Recipe in Preventing Relapse and Metastasis of Breast Cancer Patients with Negative Hormone Receptor].
    Tian HQ; Wang YJ; Wang B; Pang DM; Jin J; Liang GW; Huang XQ; Chen XZ; Yang YL; Ren G
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2017 Feb; 37(2):169-173. PubMed ID: 30650268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metaplastic Breast Carcinoma Versus Triple-Negative Breast Cancer: Survival and Response to Treatment.
    Aydiner A; Sen F; Tambas M; Ciftci R; Eralp Y; Saip P; Karanlik H; Fayda M; Kucucuk S; Onder S; Yavuz E; Muslumanoglu M; Igci A
    Medicine (Baltimore); 2015 Dec; 94(52):e2341. PubMed ID: 26717372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity.
    Reddy SM; Barcenas CH; Sinha AK; Hsu L; Moulder SL; Tripathy D; Hortobagyi GN; Valero V
    Br J Cancer; 2018 Jan; 118(1):17-23. PubMed ID: 29235566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients.
    Yamamura J; Kamigaki S; Fujita J; Osato H; Manabe H; Tanaka Y; Shinzaki W; Hashimoto Y; Komoike Y
    BMC Cancer; 2021 Apr; 21(1):476. PubMed ID: 33926418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.